Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Ronald J Bernardi"'
Autor:
Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Ronald J Bernardi, Víctor Jiménez-Yuste, Benjamin M Beckermann, Christophe Schmitt, Giuliana Ventriglia, Jerzy Windyga, Roseline d'Oiron, Paul Moorehead, Sunita Koparkar, Vanda Teodoro, Amy D Shapiro, Johannes Oldenburg, Cedric Hermans
Publikováno v:
The Lancet. Haematology, Vol. 10, no.3, p. e168-e177 (2023)
BACKGROUND: Clinical trial data are scarce for the use of prophylaxis in people with non-severe haemophilia A. The HAVEN 6 study aims to assess safety and efficacy of emicizumab prophylaxis in people with non-severe haemophilia A without factor VIII
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5495bafd43f5844c792ca78dc42aa24d
https://hdl.handle.net/2078.1/274140
https://hdl.handle.net/2078.1/274140
Autor:
Jason M. Shohet, Giorgio Milazzo, Saurabh Agarwal, Kimal Rajapakshe, Eveline Barberi, Giovanni Perini, Ronald J. Bernardi, Jan Koster, Cristian Coarfa, Zaowen Chen
Publikováno v:
Oncotarget
Oncotarget, 9(29), 20323-20338. Impact Journals
Oncotarget, 9(29), 20323-20338. Impact Journals
The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined. Neuroblastoma is p53 wild ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d660b7c2b421f9fbb7e86f68174790c
https://pubmed.ncbi.nlm.nih.gov/30042831
https://pubmed.ncbi.nlm.nih.gov/30042831
Autor:
Noah Dephoure, Susan G. Hilsenbeck, Thomas F. Westbrook, Richard A. Gibbs, Chad J. Creighton, Stephen J. Elledge, C. Kent Osborne, James G. Christensen, David J. Shields, Rachel Schiff, Jessica D. Kessler, Amritha Nair, Kristen L. Karlin, Chad A. Shaw, David A. Wheeler, Tingting Sun, Alex Renwick, Steven P. Gygi, Don X. Nguyen, Michael T. Lewis, I. Migliaccio, Ronald J. Bernardi
Publikováno v:
Cancer Research. 75:P6-11
Triple-negative breast cancer (TNBC) is a collection of diseases with distinct clinical behaviors and heterogeneous molecular features. Such clinical and genetic heterogeneity has called into question whether there are common pathogenic mechanisms (a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87afd0f469ab4365c27fc12491c177cf
https://doi.org/10.1158/1538-7445.sabcs14-p6-11-01
https://doi.org/10.1158/1538-7445.sabcs14-p6-11-01
Autor:
Nino Rainusso, Jason T. Yustein, Ronald J. Bernardi, Ryan Shuck, Lyazat Kurenbekova, Atreyi Dasgupta, Matteo Trucco, David M. Loeb
Publikováno v:
Oncotarget
// Atreyi Dasgupta 1 , Matteo Trucco 2 , Nino Rainusso 1 , Ronald J. Bernardi 1 , Ryan Shuck 1 , Lyazat Kurenbekova 1 , David M. Loeb 3 and Jason T. Yustein 1, 4, 5 1 The Faris D. Virani Ewing Sarcoma Center at The Texas Children’s Cancer and Hemat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e0b836a54d4c956140b2176f278c01c
https://pubmed.ncbi.nlm.nih.gov/29100387
https://pubmed.ncbi.nlm.nih.gov/29100387
Autor:
Guang Hu, Natalya N. Pavlova, C. Kent Osborne, Don X. Nguyen, Chunshui Zhou, Ronald J. Bernardi, Chad J. Creighton, Stephen J. Elledge, Thomas F. Westbrook, Maria F. Botero, Chad A. Shaw, David A. Wheeler, Steven P. Gygi, Earlene M. Schmitt, Jian Huang, Jessica D. Kessler, Mohamed Bentires-Alj, Richard A. Gibbs, Rachel Schiff, Mitchell Rao, Kristen L. Meerbrey, Tingting Sun, Mamie Z. Li, Noah Dephoure, Donna M. Muzny, Nicola Aceto, Susan G. Hilsenbeck, I. Migliaccio
Publikováno v:
Cell. 144:703-718
SummaryAmong breast cancers, triple-negative breast cancer (TNBC) is the most poorly understood and is refractory to current targeted therapies. Using a genetic screen, we identify the PTPN12 tyrosine phosphatase as a tumor suppressor in TNBC. PTPN12
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33866c6168bc93ce6717e565ae858bc0
https://doi.org/10.1016/j.cell.2011.02.003
https://doi.org/10.1016/j.cell.2011.02.003
Autor:
Tf. Westbrook, I. Migliaccio, CK Osborne, Maria F. Botero, Richard A. Gibbs, Earlene M. Schmitt, Stephen J. Elledge, SG Hilsenbeck, Ronald J. Bernardi, Jessica D. Kessler, Tingting Sun, Ca Shaw, D Wheeler, Don X. Nguyen, Rachel Schiff, Natalya N. Pavlova, Chad J. Creighton, Kristen L. Meerbrey
Publikováno v:
Cancer Research. 70:S6-10
Breast cancer is a collection of diseases with distinct clinical behaviors and underlying genetic causes. Triple-negative breast cancer (TNBC) is a common subtype of breast cancer that confers a particularly poor prognosis and is refractory to curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b3d15147f489c3d3d6e9fd6c783e6c9
https://doi.org/10.1158/0008-5472.sabcs10-s6-10
https://doi.org/10.1158/0008-5472.sabcs10-s6-10
Autor:
Sonal Gahlawat, Thomas F. Westbrook, Siddhartha Tyagi, Ronald J. Bernardi, Kathleen A. Scorsone, Tingting Sun, Mayra Orellana, Amritha Nair
Publikováno v:
Cancer Research. 78:A43-A43
As there is a paucity of targetable oncogenic drivers in pediatric solid tumors, we hypothesized that deficiency of select protein tyrosine phosphatases may allow proliferative signals to proceed unchecked in these cancers and that understanding thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9dec705e44f90761032c72534265306
https://doi.org/10.1158/1538-7445.pedca17-a43
https://doi.org/10.1158/1538-7445.pedca17-a43
Autor:
Cristian Coarfa, Giorgio Milazzo, Saurabh Agarwal, Ronald J. Bernardi, Zaowen Chen, Giovanni Perini, Kimal Rajapakshe, Jan Koster, Jason M. Shohet, Barbieri Eveline
Publikováno v:
Oncotarget
The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined. Neuroblastoma is p53 wild ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7b74144f17f18e72dfac13604e866f3
https://doi.org/10.18632/oncotarget.25776
https://doi.org/10.18632/oncotarget.25776
Autor:
Kathleen A. Scorsone, Ronald J. Bernardi, Thomas F. Westbrook, Sonal Gahlawat, Siddhartha Tyagi, Mayra Orellana
Publikováno v:
Cancer Research. 78:4291-4291
Pharmacologic inhibition of oncogenic ALK can yield clinical responses in a variety of cancer types, including non-small cell lung cancer, anaplastic large-cell lymphoma, and neuroblastoma; however, de novo and acquired resistance remain major proble
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91bef4ce33ef95216b468c48eda2682a
https://doi.org/10.1158/1538-7445.am2018-4291
https://doi.org/10.1158/1538-7445.am2018-4291
Autor:
Kathleen A. Scorsone, Stephen J. Elledge, Anthony C. Liang, Yuyang Li, Qikai Xu, Yumei Leng, Thomas F. Westbrook, Timothy D. Martin, Ronald J. Bernardi, Laura M. Sack, Ting Chen, Mamie Z. Li, Kamila Naxerova, Kwok-Kin Wong, Teresa Davoli, Eric C. Wooten
Publikováno v:
Cell. 173:499-514.e23
Genomics has provided a detailed structural description of the cancer genome. Identifying oncogenic drivers that work primarily through dosage changes is a current challenge. Unrestrained proliferation is a critical hallmark of cancer. We constructed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d132d1faafc4a3a72a512b5e7dce85
https://doi.org/10.1016/j.cell.2018.02.037
https://doi.org/10.1016/j.cell.2018.02.037